Daily natural supplement to lower blood PAI-1 (a clotting-related protein)
Effect of a Daily Nitric Oxide-Stimulating Supplement on Plasma PAI-1 Levels: a Six-Week, Open-Label Clinical Trial
This six-week test tries a daily natural supplement to lower blood markers of vascular aging, like PAI-1, in healthy adults without heart disease.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 35 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, Los Angeles Academic / other |
| Locations | 2 sites (Los Angeles, California and 1 other locations) |
| Trial ID | NCT07469475 on ClinicalTrials.gov |
What this trial studies
Healthy adults without a history of acute or chronic cardiovascular disease will take a daily oral supplement containing ginger extract, L-citrulline, Paullinia cupana, and muira puama for six weeks. Blood will be drawn before and after supplementation to measure a panel of markers linked to vascular aging and inflammation, including PAI-1, IL-8, PCSK9, FGF-23, CRP, and Klotho. The study aims to see whether the supplement changes these biomarker levels in ways that could reflect improved endothelial function or reduced vascular inflammation. Participants who are pregnant, current smokers, using hormonal birth control, or allergic to the ingredients are excluded.
Who should consider this trial
Good fit: Adults aged 18 and older who do not have acute or chronic cardiovascular disease, are not current smokers, are not pregnant or using hormonal birth control, and are not allergic to the listed ingredients are ideal candidates.
Not a fit: People with prior serious cardiovascular events, active cancer (other than skin cancer), current smokers, pregnant individuals, those using hormonal birth control, or those allergic to the ingredients are excluded and unlikely to receive benefit from this study.
Why it matters
Potential benefit: If successful, the supplement could lower levels of clotting- and inflammation-related proteins and potentially support healthier blood vessel function as people age.
How similar studies have performed: Some individual components such as L-citrulline and ginger have shown modest improvements in endothelial function or inflammation in small studies, but this exact combination and formulation has not been widely tested in rigorous trials.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * People of any gender at least 18 years of age who do not have a history of acute or chronic cardiovascular illnesses are eligible. Exclusion Criteria: * Younger than 18 years of age * Currently pregnant (which will be confirmed by pregnancy test for participants capable of pregnancy) * Using hormonal birth control * Current smoker * Allergy to ginger, muira puama, Paullinia cupana, or L-citrulline * Previous use of Revactin® or RM * History of serious cardiovascular events, including myocardial infarction (heart attack) or stroke * History of coronary, cardiac, or carotid surgery such as a stent, heart surgery, or endarterectomy * Active cancer of any type other than skin cancer
Where this trial is running
Los Angeles, California and 1 other locations
- UCLA — Los Angeles, California, United States (Recruiting)
- UCLA The Men's Clinic — Santa Monica, California, United States (Recruiting)
Study contacts
- Principal investigator: Sriram V Eleswarapu, MD, PhD — University of California, Los Angeles
- Study coordinator: Sriram V Eleswarapu, MD, PhD
- Email: seleswarapu@mednet.ucla.edu
- Phone: 3107943058
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.